Crucial role of the pentose phosphate pathway in malignant tumors (Review)
- Authors:
- Lin Jin
- Yanhong Zhou
-
Affiliations: The Key Laboratory of Carcinogenesis of The Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan 410078, P.R. China - Published online on: March 5, 2019 https://doi.org/10.3892/ol.2019.10112
- Pages: 4213-4221
This article is mentioned in:
Abstract
 |
 |
|
Vazquez A, Kamphorst JJ, Markert EK, Schug ZT, Tardito S and Gottlieb E: Cancer metabolism at a glance. J Cell Sci. 129:3367–3373. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Weber GF: Metabolism in cancer metastasis. Int J Cancer. 138:2061–2066. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Tan M and Cai Q: The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 356:156–164. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F and Lisanti MP: Cancer metabolism: A therapeutic perspective. Nat Rev Clin Oncol. 14:11–31. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ramos-Martinez JI: The regulation of the pentose phosphate pathway: Remember Krebs. Arch Biochem Biophys. 614:50–52. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Patra KC and Hay N: The pentose phosphate pathway and cancer. Trends Biochem Sci. 39:347–354. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kruger NJ and von Schaewen A: The oxidative pentose phosphate pathway: Structure and organisation. Curr Opin Plant Biol. 6:236–246. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Pavlova NN and Thompson CB: The emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Stincone A, Prigione A, Cramer T, Wamelink MM, Campbell K, Cheung E, Olin-Sandoval V, Grüning NM, Krüger A, Tauqeer Alam M, et al: The return of metabolism: Biochemistry and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc. 90:927–963. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Zhang Z, Zhu Y and Qin S: Glucose-6-phosphate dehydrogenase: A biomarker and potential therapeutic target for cancer. Anticancer Agents Med Chem. 14:280–289. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kathagen-Buhmann A, Schulte A, Weller J, Holz M, Herold-Mende C, Glass R and Lamszus K: Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation. Neuro Oncol. 18:1219–1229. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ju HQ, Lu YX, Wu QN, Liu J, Zeng ZL, Mo HY, Chen Y, Tian T, Wang Y, Kang TB, et al: Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer. Oncogene. 36:6282–6292. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Au SW, Gover S, Lam VM and Adams MJ: Human glucose-6-phosphate dehydrogenase: The crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. Structure. 8:293–303. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen P and Rosemeyer MA: Subunit interactions of glucose-6-phosphate dehydrogenase from human erythrocytes. Eur J Biochem. 8:8–15. 1969. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M and Yang X: p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol. 13:310–316. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ma X, Wang L, Huang, Li Y, Yang D, Li T, Li F, Sun L, Wei H, He K, et al: Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway. Nat Commun. 8:15062017. View Article : Google Scholar : PubMed/NCBI | |
|
Rao X, Duan X, Mao W, Li X, Li Z, Li Q, Zheng Z, Xu H, Chen M, Wang PG, et al: O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth. Nat Commun. 6:84682015. View Article : Google Scholar : PubMed/NCBI | |
|
Thiepold AL, Lorenz NI, Foltyn M, Engel AL, Divé I, Urban H, Heller S, Bruns I, Hofmann U, Dröse S, et al: Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death. Brain. 140:2623–2638. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Zhang X, Li Y, Shao Y, Xiao J, Zhu G and Li F: PAK4 regulates G6PD activity by p53 degradation involving colon cancer cell growth. Cell Death Dis. 8:e28202017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Peng X and Huang J: Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation. Clin Transl Oncol. 20:1145–1152. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD and Sattler M: Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 8:67639–67650. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng W, Feng Q, Liu J, Guo Y, Gao L, Li R, Xu M, Yan G, Yin Z, Zhang S, et al: Inhibition of 6-phosphogluconate dehydrogenase reverses cisplatin resistance in ovarian and lung cancer. Front Pharmacol. 8:4212017. View Article : Google Scholar : PubMed/NCBI | |
|
Shan C, Elf S, Ji Q, Kang HB, Zhou L, Hitosugi T, Jin L, Lin R, Zhang L, Seo JH, et al: Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Mol Cell. 55:552–565. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, Hitosugi T, Zhang L, Zhang S, Seo JH, et al: 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 17:1484–1496. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hitosugi T, Zhou L, Elf S, Fan J, Kang HB, Seo JH, Shan C, Dai Q, Zhang L, Xie J, et al: Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell. 22:585–600. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yao P, Sun H, Xu C, Chen T, Zou B, Jiang P and Du W: Evidence for a direct cross-talk between malic enzyme and the pentose phosphate pathway via structural interactions. J Biol Chem. 292:17113–17120. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu Z, Guo W, Wang Q, Chen Z, Huang S, Zhao F, Yao M, Zhao Y and He X: MicroRNA-124 reduces the pentose phosphate pathway and proliferation by targeting PRPS1 and RPIA mRNAs in human colorectal cancer cells. Gastroenterology. 149:1587–1598.e11. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chou YT, Jiang JK, Yang MH, Lu JW, Lin HK, Wang HD and Yuh CH: Identification of a noncanonical function for ribose-5-phosphate isomerase A promotes colorectal cancer formation by stabilizing and activating β-catenin via a novel C-terminal domain. PLoS Biol. 16:e20037142018. View Article : Google Scholar : PubMed/NCBI | |
|
Ciou SC, Chou YT, Liu YL, Nieh YC, Lu JW, Huang SF, Chou YT, Cheng LH, Lo JF, Chen MJ, et al: Ribose-5-phosphate isomerase A regulates hepatocarcinogenesis via PP2A and ERK signaling. Int J Cancer. 137:104–115. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Benito A, Polat IH, Noé V, Ciudad CJ, Marin S and Cascante M: Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome. Oncotarget. 8:106693–106706. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, Law CT, Wong CM, Cai Z, Wong CC and Ng IO: Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci USA. 113:E725–E734. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kamenisch Y, Baban TSA, Schuller W, von Thaler AK, Sinnberg T, Metzler G, Bauer J, Schittek B, Garbe C, Rocken M and Berneburg M: UVA-irradiation induces melanoma invasion via the enhanced Warburg effect. J Invest Dermatol. 136:1866–1875. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Huang D, McArthur D, Boros L, Nissen N and Heaney A: Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res. 70:6368–6376. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Coy JF, Dressler D, Wilde J and Schubert P: Mutations in the transketolase-like gene TKTL1: Clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab. 51:257–273. 2005.PubMed/NCBI | |
|
Coy JF, Dübel S, Kioschis P, Thomas K, Micklem G, Delius H and Poustka A: Molecular cloning of tissue-specific transcripts of a transketolase-related gene: Implications for the evolution of new vertebrate genes. Genomics. 32:309–316. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 94:578–585. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lange CA, Tisch-Rottensteiner J, Böhringer D, Martin G, Schwartzkopff J and Auw-Haedrich C: Enhanced TKTL1 expression in malignant tumors of the ocular adnexa predicts clinical outcome. Ophthalmology. 119:1924–1929. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lin CC, Chen LC, Tseng VS, Yan JJ, Lai WW, Su WP, Lin CH, Huang CY and Su WC: Malignant pleural effusion cells show aberrant glucose metabolism gene expression. Eur Respir J. 37:1453–1465. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Zur Hausen A, Coy JF and Löchelt M: Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer. 124:1330–1337. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kočevar N, Odreman F, Vindigni A, Grazio SF and Komel R: Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers. World J Gastroenterol. 18:1216–1228. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Guo K, Gao D, Kang X, Jiang K, Li Y, Sun L, Zhang S, Sun C, Liu X, et al: Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples. Cancer Lett. 313:154–166. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh BS, Huang LW, Su SJ, Cheng HL, Hu YC, Hung TC and Chang KL: Combined arginine and ascorbic acid treatment induces apoptosis in the hepatoma cell line HA22T/VGH and changes in redox status involving the pentose phosphate pathway and reactive oxygen and nitrogen species. J Nutr Biochem. 22:234–241. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Zhang B, Yao W, Zhang C, Wan L and Zhang Y: APC-Cdh1 regulates neuronal apoptosis through modulating glycolysis and pentose-phosphate pathway after oxygen-glucose deprivation and reperfusion. Cell Mol Neurobiol. 39:123–135. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Senyilmaz D and Teleman A: Chicken or the egg: Warburg effect and mitochondrial dysfunction. F1000Prime Rep. 7:412015. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson JE: Isozymes of mammalian hexokinase: Structure, subcellular localization and metabolic function. J Exp Biol. 206:2049–2057. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Gu J, Singh A, Xue K, Mavis C, Barth M, Yanamadala V, Lenz P, Grau M, Lenz G, Czuczman MS and Hernandez-Ilizaliturri FJ: Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget. 9:4020–4033. 2017.PubMed/NCBI | |
|
Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, et al: Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 24:213–228. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
An MX, Li S, Yao HB, Li C, Wang JM, Sun J, Li XY, Meng XN and Wang HQ: BAG3 directly stabilizes Hexokinase 2 mRNA and promotes aerobic glycolysis in pancreatic cancer cells. J Cell Biol. 216:4091–4105. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hoppe-Seyler K, Honegger A, Bossler F, Sponagel J, Bulkescher J, Lohrey C and Hoppe-Seyler F: Viral E6/E7 oncogene and cellular hexokinase 2 expression in HPV-positive cancer cell lines. Oncotarget. 8:106342–106351. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ju HQ, Zhan G, Huang A, Sun Y, Wen S, Yang J, Lu WH, Xu RH, Li J, Li Y, et al: ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. Leukemia. 31:2143–2150. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Duan Z, Nugent Z, Zou JX, Borowsky AD, Zhang Y, Tepper CG, Li JJ, Fiehn O, Xu J, et al: Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Lett. 378:69–79. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, et al: LPA induces metabolic reprogramming in ovarian cancer via a pseudohypoxic response. Cancer Res. 78:1923–1934. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Moon JS, Kim HE, Koh E, Park SH, Jin WJ, Park BW, Park SW and Kim KS: Krüppel-like factor 4 (KLF4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (PFKP) in breast cancer. J Biol Chem. 286:23808–23816. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, et al: Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 58:182–191. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cabrera R, Baez M, Pereira HM, Caniuguir A, Garratt RC and Babul J: The crystal complex of phosphofructokinase-2 of Escherichia coli with fructose-6-phosphate: Kinetic and structural analysis of the allosteric ATP inhibition. J Biol Chem. 286:5774–5783. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA III, Peters EC, Driggers EM and Hsieh-Wilson LC: Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science. 337:975–980. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Peng Z, Wang S, Yang L, Chen Y, Kong X, Song S, Pei P, Tian C, Yan H, et al: KRAB-type zinc-finger proteins PITA and PISA specifically regulate p53-dependent glycolysis and mitochondrial respiration. Cell Res. 28:572–592. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JH, Liu R, Li J, Zhang C, Wang Y, Cai Q, Qian X, Xia Y, Zheng Y, Piao Y, et al: Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat Commun. 8:9492017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, Gao H, Yang G, Williams JA, Suski JM, et al: The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 546:426–430. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim NH, Cha YH, Lee J, Lee SH, Yang JH, Yun JS, Cho ES, Zhang X, Nam M, Kim N, et al: Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress. Nat Commun. 8:143742017. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto T, Takano N, Ishiwata K, Ohmura M, Nagahata Y, Matsuura T, Kamata A, Sakamoto K, Nakanishi T, Kubo A, et al: Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat Commun. 5:34802014. View Article : Google Scholar : PubMed/NCBI | |
|
Gui DY, Lewis CA and Vander Heiden MG: Allosteric regulation of PKM2 allows cellular adaptation to different physiological states. Sci Signal. 263:pe72013. | |
|
Fukuda S, Miyata H, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M and Doki Y: Pyruvate kinase M2 modulates esophageal squamous cell carcinoma chemotherapy response by regulating the pentose phosphate pathway. Ann Surg Oncol. 22 (Suppl 3):S1461–S1468. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, et al: PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 155:397–409. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Keller KE, Tan IS and Lee YS: SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science. 338:1069–1072. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK and Lu Z: PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 150:685–696. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, et al: Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science. 334:1278–1283. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 145:732–744. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chaneton B, Hillmann P, Zheng L, Martin ACL, Maddocks ODK, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, et al: Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 491:458–462. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Goh GB, Li JW, Chang PE, Chow KY and Tan CK: Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades. Hepatol Commun. 1:564–571. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Busby J, Mills K, Zhang S, Liberante F and Cardwell C: Postdiagnostic Calcium channel blocker use and breast cancer mortality: A population-based cohort study. Epidemiology. 29:407–413. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nanavaty P, Alvarez MS and Alberts WM: Lung cancer screening: Advantages, controversies, and applications. Cancer Control. 21:9–14. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lu M, Lu L, Dong Q, Yu G, Chen J, Qin L, Wang L, Zhu W and Jia H: Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai). 50:370–380. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kowalik M, Guzzo G, Morandi A, Perra A, Menegon S, Masgras I, Trevisan E, Angioni MM, Fornari F, Quagliata L, et al: Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. Oncotarget. 7:32375–32393. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kong DH, Li S, Du ZX, Liu C, Liu BQ, Li C, Zong ZH and Wang HQ: BAG3 elevation inhibits cell proliferation via direct interaction with G6PD in hepatocellular carcinomas. Oncotarget. 7:700–711. 2016.PubMed/NCBI | |
|
Hong X, Song R, Song H, Zheng T, Wang J, Liang Y, Qi S, Lu Z, Song X, Jiang H, et al: PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut. 63:1635–1647. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Maruyama H, Kleeff J, Wildi S, Friess H, Büchler MW, Israel MA and Korc M: Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol. 155:815–822. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Yin X, Tang B, Li JH, Wang Y, Zhang L, Xie XY, Zhang BH, Qiu SJ, Wu WZ and Ren ZG: ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway. J Exp Clin Cancer Res. 36:1662017. View Article : Google Scholar : PubMed/NCBI | |
|
DeWaal D, Nogueira V, Terry AR, Patra KC, Jeon SM, Guzman G, Au J, Long CP, Antoniewicz MR and Hay N: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 9:4462018. View Article : Google Scholar : PubMed/NCBI | |
|
Lin YH, Wu MH, Huang YH, Yeh CT, Cheng ML, Chi HC, Tsai CY, Chung IH, Chen CY and Lin KH: Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology. 67:188–203. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jin F, Wang Y, Zhu Y, Li S, Liu Y, Chen C, Wang X, Zen K and Li L: The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma. Sci Rep. 7:30892017. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Jin R, Wang W, Zhang T, Sang J, Li N, Han Q, Zhao W, Li C and Liu Z: STAT3 regulates glycolysis via targeting hexokinase 2 in hepatocellular carcinoma cells. Oncotarget. 8:24777–24784. 2017.PubMed/NCBI | |
|
Lee H, Kim H, Son T, Jeong Y, Kim SU, Dong SM, Park YN, Lee JD, Lee JM and Park JH: Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma. Oncotarget. 7:41798–41810. 2016.PubMed/NCBI | |
|
Dong T, Kang X, Liu Z, Zhao S, Ma W, Xuan Q, Liu H, Wang Z and Zhang Q: Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer. Tumour Biol. 37:8159–8168. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pu H, Zhang Q, Zhao C, Shi L, Wang Y, Wang J and Zhang M: Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma. World J Surg Oncol. 13:3232015. View Article : Google Scholar : PubMed/NCBI | |
|
Tseng CW, Kuo WH, Chan SH, Chan HL, Chang KJ and Wang LH: Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the α-ketoglutarate signaling pathway. Cancer Res. 78:2799–2812. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Yang Y, Yuan F, Huang J, Xu W, Mao B, Yuan Z and Bi W: TNFα-YAP/p65-HK2 axis mediates breast cancer cell migration. Oncogenesis. 6:e3832017. View Article : Google Scholar : PubMed/NCBI | |
|
Gallagher LE, Radhi OA, Abdullah MO, McCluskey AG, Boyd M and Chan EYW: Lysosomotropism depends on glucose: A chloroquine resistance mechanism. Cell Death Dis. 8:e30142017. View Article : Google Scholar : PubMed/NCBI | |
|
Marini C, Bianchi G, Buschiazzo A, Ravera S, Martella R, Bottoni G, Petretto A, Emionite L, Monteverde E, Capitanio S, et al: Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. Sci Rep. 6:195692016. View Article : Google Scholar : PubMed/NCBI | |
|
Doménech E, Maestre C, Esteban-Martínez L, Partida D, Pascual R, Fernández-Miranda G, Seco E, Campos-Olivas R, Pérez M, Megias D, et al: AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol. 17:1304–1316. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ge X, Lyu P, Gu Y, Li L, Li J, Wang Y, Zhang L, Fu C and Cao Z: Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: Modulation of PFKFB3 activation. Biochem Biophys Res Commun. 464:862–868. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dasgupta S, Rajapakshe K, Zhu B, Nikolai BC, Yi P, Putluri N, Choi JM, Jung SY, Coarfa C, Westbrook TF, et al: Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 556:249–254. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Z, Li M, Zhang L, Zhao H, Şahin Ö, Chen J, Zhao JJ, Songyang Z and Yu D: Oncogenic kinase-induced PKM2 tyrosine 105 phosphorylation converts non-oncogenic PKM2 to a tumor promoter and induces cancer stem-like cells. Cancer Res. 78:2248–2261. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Singh S, Narayanan S, Biswas K, Gupta A, Ahuja N, Yadav S, Panday RK, Samaiya A, Sharan SK and Shukla S: Intragenic DNA methylation and BORIS-mediated cancer-specific splicing contribute to the Warburg effect. Proc Natl Acad Sci USA. 114:11440–11445. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Giatromanolaki A, Sivridis E, Arelaki S and Koukourakis M: Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. Exp Lung Res. 43:167–174. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nagashio R, Oikawa S, Yanagita K, Hagiuda D, Kuchitsu Y, Igawa S, Naoki K, Satoh Y, Ichinoe M, Murakumo Y, et al: Prognostic significance of G6PD expression and localization in lung adenocarcinoma. Biochim Biophys Acta Proteins Proteom. 1867:38–46. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hong W, Cai P, Xu C, Cao D, Yu W, Zhao Z, Huang M and Jin J: Inhibition of Glucose-6-phosphate dehydrogenase reverses cisplatin resistance in lung cancer cells via the redox system. Front Pharmacol. 9:432018. View Article : Google Scholar : PubMed/NCBI | |
|
Chan B, VanderLaan P and Sukhatme VP: 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochem Biophys Res Commun. 439:247–251. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kayser G, Sienel W, Kubitz B, Mattern D, Stickeler E, Passlick B, Werner M and Zur Hausen A: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 43:719–724. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lu H and Zhu H: Effect of siRNA-mediated gene silencing of transketolase on A549 lung cancer cells. Oncol Lett. 14:5906–5912. 2017.PubMed/NCBI | |
|
Wang H, Wang L, Zhang Y, Wang J, Deng Y and Lin D: Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int. 16:92016. View Article : Google Scholar : PubMed/NCBI | |
|
De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP and Del Vecchio S: Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res. 21:5110–5120. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J and Weber W: Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 12:5659–5667. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang K, Zhang M, Jiang H, Liu F, Liu H and Li Y: Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2. Biomed Pharmacother. 105:545–552. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng X, Liu F, Liu H, Wang G and Hao H: Enhanced glycometabolism as a mechanism of NQO1 potentiated growth of NSCLC revealed by metabolomic profiling. Biochem Biophys Res Commun. 496:31–36. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Minchenko OH, Ogura T, Opentanova IL, Minchenko DO, Ochiai A, Caro J, Komisarenko SV and Esumi H: 6-Phospho-fructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor. Ukr Biokhim Zh (1999). 77:46–50. 2005.PubMed/NCBI | |
|
Yang J, Li J, Le Y, Zhou C, Zhang S and Gong Z: PFKL/miR-128 axis regulates glycolysis by inhibiting AKT phosphorylation and predicts poor survival in lung cancer. Am J Cancer Res. 6:473–485. 2016.PubMed/NCBI |
